1 March 2020 in Journal of Autoimmunity
11 December 2023 in The Journal of Immunology
Oxidants participate in lymphocyte activation and function. We previously demonstrated that eliminating the activity of NADPH oxidase 2 (NOX2) significantly impaired the effectiveness of autoreactive CD8+ CTLs. However, the molecular mechanisms impacting CD8+ T cell function remain unknown. In the present study, we examined the role of NOX2 in both NOD mouse and human CD8+ T cell function. Genetic ablation or chemical inhibition of NOX2 in CD8+ T cells significantly suppressed activation-induced expression of the transcription factor T-bet, the master transcription factor of the Tc1 cell lineage, and T-bet target effector genes such as IFN-γ and granzyme B. Inhibition of NOX2 in both human and mouse CD8+ T cells prevented target cell lysis. We identified that superoxide generated by NOX2 must be converted into hydrogen peroxide to transduce the redox signal in CD8+ T cells. Furthermore, we show that NOX2-generated oxidants deactivate the tumor suppressor complex leading to activation of RheB and subsequently mTOR complex 1. These results indicate that NOX2 plays a nonredundant role in TCR-mediated CD8+ T cell effector function.
10 April 2024 in Academic Pediatrics
18 November 2025 in Current Rheumatology Reports
Purpose of Review: Until recently, the absence of validated, pediatric-specific classification criteria for juvenile spondyloarthritis (JSpA) limited targeted clinical trials evaluating treatment efficacy and advancements in understanding the natural history in pediatric-onset disease. There is an urgent need for efficacy and effectiveness studies in this understudied group. Recent Findings: Most children with JSpA continue to experience disease activity despite current therapies and generally have worse outcomes than those with other juvenile arthritis forms. Fewer than 20% achieve remission within five years of diagnosis. Axial involvement is a distinct manifestation warranting separate study and management, as it does not respond to conventional agents like methotrexate used for peripheral arthritis. Comparative effectiveness data are lacking, and no medications are FDA-approved specifically for “juvenile spondyloarthritis” or “juvenile ankylosing spondylitis.” The only FDA-approved therapy for enthesitis-related arthritis (ERA) is secukinumab. In 2024, pediatric classification criteria for axial disease in JSpA were published. These criteria include seven domains: MRI inflammation, MRI structural lesions, pain chronicity, pain pattern, pain location, stiffness, and genetic association. Imaging evidence of axial disease is necessary but not sufficient for classification. Summary: This review provides an overview of JSpA epidemiology, current and emerging classification criteria, and highlights the key features of the newly validated pediatric axial JSpA classification criteria.